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Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
cause the life-limiting hereditary disease, cystic fibrosis (CF). Decreased or absent
functional CFTR protein in airway epithelial cells leads to abnormally viscous mucus and
impaired mucociliary transport, resulting in bacterial infections and inflammation causing
progressive lung damage. There are more than 2000 known variants in the CFTR gene.
A subset of CF individuals with specific CFTR mutations qualify for pharmacotherapies of
variable efficacy. These drugs, termed CFTR modulators, address key defects in protein
folding, trafficking, abundance, and function at the apical cell membrane resulting from
specific CFTR mutations. However, some CFTR mutations result in little or no CFTR
mRNA or protein expression for which a pharmaceutical strategy is more challenging
and remote. One approach to rescue CFTR function in the airway epithelium is to
replace cells that carry a mutant CFTR sequence with cells that express a normal copy
of the gene. Cell-based therapy theoretically has the potential to serve as a one-time
cure for CF lung disease regardless of the causative CFTR mutation. In this review,
we explore major challenges and recent progress toward this ambitious goal. The
ideal therapeutic cell would: (1) be autologous to avoid the complications of rejection
and immune-suppression; (2) be safely modified to express functional CFTR; (3) be
expandable ex vivo to generate sufficient cell quantities to restore CFTR function; and
(4) have the capacity to engraft, proliferate and persist long-term in recipient airways
without complications. Herein, we explore human bronchial epithelial cells (HBECs) and
induced pluripotent stem cells (iPSCs) as candidate cell therapies for CF and explore
the challenges facing their delivery to the human airway.
Keywords: cystic fibrosis, cell-based therapy, induced pluripotent stem cells, human bronchial epithelial cells,
engraftment
INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive, multisystem, genetic disease caused by mutations in
the cystic fibrosis transmembrane conductance regulator (CFTR) gene resulting in deficient and/or
defective CFTR protein (Cutting, 2014; Ratjen et al., 2015). CFTR is an anion channel present
across a number of epithelia including the lungs, intestine, sinuses, pancreas, biliary tree, and vas
deferens. The consequences of CFTR dysfunction are pronounced in the lungs where ineffective
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chloride and bicarbonate ion transport results in an abnormally
viscous and acidic apical surface layer (ASL). This abnormal
environment is colonized by bacteria in early life and a cycle
of infection and inflammation results in bronchiectasis and
end-stage lung disease (Ratjen et al., 2015). Disease severity is
determined to a large extent by the causative CFTR mutation(s).
Over 2,000 variants in CFTR have been described, of which
approximately 300 have been determined to be pathogenic
(cftr2.org). These variants or combinations of variants have
differing effects on the amount and function of CFTR protein.
Some variants are associated with milder disease or particular
organ involvement while others may be associated with very
severe disease. For classification purposes, these mutations are
grouped into six classes (I-VI) based on their effect on CFTR
including: no protein synthesis (class I), protein misfolding (class
II), dysfunctional channel gating (class III), reduced conductance
(class IV), insufficient CFTR protein due to abnormal RNA
splicing (class V), or increased protein turnover (class VI).
Mucus clearance techniques, antibiotics, and lung transplan-
tation significantly improve the life expectancy of CF individuals.
The recent discovery of CFTR modulators has ushered in a new
era of precision medicine for CF patients with mutations that
result in some residual druggable CFTR protein. For example,
the major defect in patients with the class III mutation G551D
is diminished channel activity at the apical surface. Ivacaftor is
an FDA approved CFTR potentiator that increases CFTR activity
and results in clinical improvement in patients with at least one
copy of the G551D mutation (Ramsey et al., 2011). F508del
is the most common CFTR mutation affecting approximately
90% of CF patients (Cutting, 2014). This mutation results in
defective folding and trafficking of the CFTR protein. Corrector
molecules such as lumacaftor and tezacaftor in conjunction with
ivacaftor result in increased CFTR activity and some clinical
improvement though not as robust as the response of gating
and residual function mutations to ivacaftor therapy (Rowe
et al., 2017; Taylor-Cousar et al., 2018). Recent progress with
“triple combination” regimens including two correctors plus
the potentiator ivacaftor indicates increased efficacy for those
harboring the class II F508del mutation (Davies et al., 2018;
Keating et al., 2018). Class I mutations are non-sense, frame-
shift or splice variants that result in premature termination of the
CFTR transcript and no CFTR protein. These patients currently
have no targeted therapies available and there are many barriers
to a pharmacological approach to treatment.
The challenge is clear, how do we identify and develop
effective therapies for all CF individuals? In theory, replacing
the mutant CFTR sequence with the normal sequence could
restore CFTR function regardless of mutation. Generally, this
might be achieved by one of three approaches: (1) in vivo delivery
of normal CFTR sequence, e.g., via viral vectors, (2) in vivo
editing of the mutant CFTR sequence or, (3) delivery of cells
carrying the normal CFTR sequence to replace cells carrying the
mutant sequence. In this review, we focus on the approach of cell-
based therapy for CF lung disease. Although there are compelling
examples of effective cell-based therapies, such as hematopoietic
stem cell transplantation, there are many challenges facing such
an approach for lung disease. What cell type is best suited
to restore CFTR function to the airways? How might cells be
effectively but safely delivered to a CF patient’s lungs? Here
we will review the most promising cellular candidates to treat
CF, human bronchial epithelial cells (HBECs) and induced
pluripotent stem cells (iPSCs). Finally, we will discuss the major
hurdles facing the field of CF cell-based therapeutics, including
delivery and engraftment of cells into a diseased host.
OVERVIEW OF AIRWAY EPITHELIAL
BIOLOGY IN CF
Airway epithelial cells, including club, goblet, multi-ciliated, basal
and neuroendocrine cells occupy a vital environmental interface.
Their normal physiological function is essential to maintain
respiratory tract health, and the cells are intimately involved
in the pathogenesis of multiple respiratory tract maladies,
including the common diseases asthma and chronic obstructive
pulmonary disease (Randell et al., 2009). In CF, a dehydrated
and acidic ASL impairs critical innate defense mechanisms
including mucociliary clearance (Randell et al., 2006; Button
et al., 2012; Stoltz et al., 2015). There is current debate on the
airway cell types that express CFTR, but it is detected in the
submucosal glands (Jiang and Engelhardt, 1998) of the airway
and in certain surface epithelial cells including multi-ciliated
cells (low expression) and in the recently described pulmonary
ionocyte (high expression) (Jiang and Engelhardt, 1998; Montoro
et al., 2018; Plasschaert et al., 2018). There is debate whether cell
autonomous loss of CFTR is hyper-inflammatory per se, but the
combination of mucus stasis and chronic infection clearly results
in highly inflamed CF airways (Roesch et al., 2018). Complex
interactions during infection stemming from the epithelial defect
ultimately cascade into pathologic changes including extensive
mucus obstruction, ectasis of bronchi and bronchioles, and
consequent loss of pulmonary function (Figure 1). It is likely
that significant structural damage to the airways and surrounding
parenchyma becomes irreversible, and a goal for airway epithelial




Epithelial cell proliferation in the lung is relatively quiescent
at steady state, but this organ retains the ability to regenerate
rapidly after injury (Hegab et al., 2012). Much has been learned
in recent years about lung stem cells and their roles in repair
and regeneration, with particular emphasis on the alveolar
parenchyma (Hogan et al., 2014; Kotton and Morrisey, 2014).
Cell-based therapy for CF will logically be focused on the
conducting airway epithelium, the primary site for mucus stasis,
infection, and inflammation. The airways harbor distinct cell
populations along the proximal to distal axis that exhibit self-
renewal and differentiation capacity. Here, we propose that
HBECs may serve as candidates for autologous cell therapy
of CF. We review the stem cell properties of HBECs with
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FIGURE 1 | Normal vs. CF Airway. Schematic drawings of normal and CF airways, illustrating selected components of epithelial apical ion transport. (A) Secreted
mucins are produced by submucosal glands in the large airways and surface goblet cells, forming the overlying, mucin-rich component of the airway surface layer
(ASL). This layer is normally transported by effective beating of cilia in the periciliary layer (PCL). ASL hydration is largely controlled by the balance of chloride
secretion through CFTR and sodium reabsorption by the epithelial sodium channel (ENaC). (B) Mucin overproduction from hypertrophic submucosal glands and
hyperplastic surface goblet cells characterize the CF large airways. Non-functional or absent CFTR leads to diminished chloride transport and increased sodium
transport through ENaC. Airway dehydration reduces the PCL, impairing mucociliary transport. Accumulation of thick, sticky mucus increases overall ASL thickness
and promotes a low pH environment favoring chronic bacterial infection and inflammation. The CF ASL environment is a likely barrier for cell therapy.
a focus on the unique advantages and challenges posed for
therapeutic translation.
STEM CELLS IN THE CONDUCTING
AIRWAYS
The human conducting airways are composed of a pseudo-
stratified epithelium extending from the trachea to the proximal
end of small bronchioles. The predominant evidence is that basal
cells are the stem cells in this region (Rock et al., 2009). Basal cells
are relatively undifferentiated and express a number of classic
markers including TP63 and KRT5. The regenerative capacity of
basal cells has been extensively demonstrated through in vitro
clonal growth assays, tracheal graft regeneration, and in vivo
lineage tracing studies (Gray et al., 1991; Liu et al., 1994; Hong
et al., 2004; Rock et al., 2009). Basal cells have the capacity to
differentiate into the major cell types of the conducting airways
including club (previously Clara) cells (Schoch et al., 2004; Rock
et al., 2009), pulmonary neuroendocrine cells (Montoro et al.,
2018), the recently described pulmonary ionocyte (Montoro
et al., 2018; Plasschaert et al., 2018), and serous and mucus cells
in the glands (Hegab et al., 2012, 2014). It is thought that ciliated
and goblet cells are generated through a club cell intermediate
(Tata et al., 2013; Widdicombe and Wine, 2015), but recent single
cell mRNA sequencing studies also suggests direct differentiation
of basal cells into ciliated cells (Plasschaert et al., 2018). Basal cell
differentiation into pulmonary ionocytes and ciliated cells (either
directly or indirectly) is of particular interest for CF cell therapy
as these cell types express CFTR and are primarily responsible
for epithelial ion transport (Rock et al., 2009; Montoro et al.,
2018). The ability of lung basal cells to self-renew and replace
luminal CFTR-expressing cell types is vital for cell therapy to be
long-lasting.
The basal cell population is likely heterogeneous, containing
subpopulations with different proliferation and differentiation
capacities. At steady state, basal cell subsets express early
differentiation markers for club or ciliated cells including
the intracellular domain of Notch2 (N2ICD) or the proto-
oncogene transcription factor MYB (C-Myb), respectively,
suggesting subpopulations already primed for differentiation
(Pardo-Saganta et al., 2015; Watson et al., 2015). Mechanisms
regulating lung cell development, homeostatic maintenance,
and repair have been recently reviewed (Lee and Rawlins,
2018). However, there is still debate about which cell lineage
model is most applicable to the human pseudostratified airway
epithelium. Are there rare populations of stem cells in specific
niches that undergo asymmetric divisions, generating committed
downstream progenitors, or is the stem cell compartment
more widely distributed and stochastically regulated? While
cell harvesting, gene correction, expansion, and delivery of
intermediate progenitors may be efficacious, it is logical
that starting with cells exhibiting extensive growth potential
and differentiation capacity would be advantageous. Thus,
identifying basal cell subsets and gene signatures corresponding
to high clonal growth capacity remains an important goal
that will theoretically serve as the basis for efficacious CF
cell therapy.
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Additional cell types within the airways should be considered
as alternative candidates to restore CFTR function to the
epithelium. Columnar epithelial cells from the pseudostratified
regions demonstrate extensive plasticity in which they can
dedifferentiate into basal cells (Tata and Rajagopal, 2017). Studies
in the porcine model of CF suggest the importance of submucosal
gland dysfunction in CF pathogenesis (Hoegger et al., 2014)
and lineage tracing in mice illustrates a key role for gland
myoepithelial cells in repair (Lynch et al., 2018; Tata et al.,
2018). The ability to access, propagate and correct human gland
myoepithelial cells, and their ultimate return to gland tubular and
acinar niches will require more study.
OBTAINING, EXPANDING, AND GENE
CORRECTING HBECS
Conceptually, HBECs can be obtained from the lungs of CF
individuals using one of three minimally invasive techniques,
induced sputum sample collection, bronchiolar lavage, and
endobronchial brushing or biopsy. These methods yield
approximately 2 × 103, 5.5 × 103, and 2 × 106 cells, respectively
(Mou et al., 2012; Pollock et al., 2013; Butler et al., 2016).
Considering how few cells effectively engraft by current
approaches, the paucity of HBEC starting materials poses a
considerable challenge to their use in cell therapy. As such,
autologous cell-based therapy for CF with somatic epithelial
cells will likely require in vitro culture for both cell expansion
and gene correction. Fortunately, there is a long history of cell
culture techniques to expand and subsequently differentiate a
predominantly basal cell population from mouse and human
large airways (see Table 1 and Bove and Randell, 2015).
Conventional expansion methods can be augmented to increase
population doublings using dual SMAD inhibition or Rho
kinase inhibition along with irradiated mouse 3T3-J2 fibroblasts
co-culture (Suprynowicz et al., 2012; Mou et al., 2016). Key
reagents such as irradiated 3T3-J2 feeder cells and irradiated
serum developed for keratinocytes have been approved for
clinical applications by some regulatory authorities and can be,
similarly, employed in modern protocols to expand primary
HBECs (Suprynowicz et al., 2012; Gentzsch et al., 2017).
While the larger airways are lined by a tall pseudostratified
epithelium the more distal bronchi and bronchioles are lined
by a progressively shorter epithelium, in which basal cells
eventually extinguish. In the last generations of the small
airways, the epithelium becomes simple columnar to cuboidal
where stem cells are thought to be contained in the club
cell compartment, with an independent lineage existing among
pulmonary neuroendocrine cells (Hogan et al., 2014), although
pulmonary neuroendocrine cell generation of club and ciliated
cells has been observed (Song et al., 2012). This distal region
is an important target since small airway obstruction and air
trapping is thought to be a defining feature of early CF (Rosenow
et al., 2017). Culture methods for human small airway epithelial
cells are less well developed than for the large airway, and cells
of the smallest bronchioles appear to be more dependent on
mesenchymal signals (Lee et al., 2017; Zepp et al., 2017). Specific
TABLE 1 | Key studies in the development of culture methods for HBECs and
directed differentiation protocols to derive airway epithelial cells from iPSCs.
Human bronchial epithelial cell culture
methods
Reference
Clonal growth of human bronchial epithelial cells Lechner et al., 1981
Detailed description of a media for proliferation of
human bronchial epithelial cells on plastic
Lechner and LaVeck,
1985
Differentiation of serially passaged cells at an
air-liquid interface (ALI)
Gray et al., 1996
Current detailed methods for ALI cultures using
proprietary reagents
Neuberger et al., 2011




Detailed methods for Conditionally Reprogrammed
Cells (CRC, with feeder cells)
Gentzsch et al., 2017;
Liu et al., 2017
Dual SMAD inhibition method for cell expansion Mou et al., 2016
Method allowing clonal expansion of CRC primary
HBECs
Peters-Hall et al., 2018
CRC method with proprietary media and no feeder
cells
Zhang et al., 2018
Derivation of human airway epithelial cells from iPSCs
TGFβ/BMP inhibition required to generate anterior
foregut endoderm from iPSC
Green et al., 2011
Differentiation of human CF iPSCs into airway
epithelial cells
Mou et al., 2012
Efficient differentiation of human iPSCs into lung
epithelial cells comprised of both proximal and
distal epithelial cells
Huang et al., 2013
Generation of multiciliated cells from human iPSCs Firth et al., 2014
Human iPSC-derived lung organoids composed of
epithelium and mesoderm
Dye et al., 2015
Surface marker sort method (Carboxypeptidase M)
and culture conditions to generate neuroendocrine
and functional multiciliated cells
Konishi et al., 2016
Fluorescent lineage reporters to purify early lung
progenitors and generate epithelial-only organoid
Hawkins et al., 2017
Wnt withdrawal after early lung specification
required for airway patterning
McCauley et al., 2017
Engraftment of iPSC-derived similar to embryonic
lung-tips into immunocompromised mouse lungs
Miller et al., 2018
efforts to better understand human small airway stem cells, their
propagation, and eventual engraftment are required.
There have been tremendous advances in genome editing
techniques in the last decade, including zinc-finger nucleases,
transcription activator-like effector nucleases (TALENs), and
the clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 technique (Zhang et al., 2014). While of utmost
importance for correcting a monogenic but complex lung disease
such as CF, optimal methods for CFTR gene correction of HBECs
with minimal off target, potentially carcinogenic risks, followed
by cell expansion that maintains long-lived basal stem cells
remain to be determined.
INDUCED PLURIPOTENT STEM
CELLS (iPSCS)
iPSCs have several features relevant to their suitability as
a source for cell-based therapies. Pluripotency refers to the
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capacity to differentiate into all cell types in the body. iPSCs
can now be routinely generated from any human while
retaining an individual’s unique genetic information, without
the need for an invasive procedure. The capacity of these
cells to proliferate while retaining pluripotency means sufficient
numbers for cell-based therapy might someday be feasible.
In the following section we review the essential studies that
made the discovery of iPSCs possible, summarize the recent
progress in deriving lung epithelial cells from iPSCs (Table 1),
particularly cell types relevant to CF, and finally highlight the
many challenges to be addressed before these cells can be
transplanted into CF recipients.
HISTORY OF iPSCS
In 2006, Takahashi and Yamanaka made the remarkable discovery
that the overexpression of four key factors in somatic cells
could “re-program” cells into iPSCs (Takahashi and Yamanaka,
2006; Takahashi et al., 2007). This breakthrough was made
possible by decades of prior work in the field of embryonic
stem cells (ESCs) that identified: (1) the transient presence
of a population of pluripotent stem cells in the developing
embryo, (2) the culture conditions sufficient to capture, in vitro
expand, and maintain the pluripotency of cells isolated from early
embryos, and (3) the gene-regulatory networks that control the
ground-state of pluripotency (Solter et al., 1970; Stevens, 1970;
Evans and Kaufman, 1981; Smith, 2001). Given the regenerative
potential of ESCs there was much initial enthusiasm for their
therapeutic promise but also controversy over the ethical and
moral considerations regarding the use of fetal tissue. From
a scientific perspective the main drawback for using ESCs as
a cell-based therapy was that even if the cell type of interest
could be generated efficiently and safely, the cells would be
allogeneic to the recipient and the issues of rejection and
immunosuppression that limit the effectiveness of solid organ
transplants would persist. Dr. Jim Gurdon’s pioneering nuclear
transfer experiments in the 1960s first suggested the feasibility
of reprogramming a somatic cell into an autologous pluripotent
stem cell (Gurdon, 1962). When a frog egg nucleus was replaced
with an intestinal cell nucleus a viable tadpole was produced
confirming that the cellular identity could be “reset” to a
pluripotent state. Takahashi and Yamanaka set about screening
candidate factors that might have the same effect. They identified
four factors, Oct4, Sox2, Klf4, and c-Myc that were sufficient
to reprogram mouse somatic cells (initially skin fibroblasts)
into pluripotent stem cells. These “induced” pluripotent stem
cells were virtually indistinguishable from ESCs based on their
similar transcriptional profiles and capacity to differentiate
into all three germ layers when injected subcutaneously in
a teratoma assay. Remarkably, iPSCs also contributed to
embryogenesis when injected into a blastocyst. One year
later, the same four factors were confirmed to reprogram
human fibroblasts into iPSCs. Crucial to the emerging field of
regenerative medicine, iPSCs have four key characteristics: (1)
they are generated from the potential recipient, i.e., autologous,
(2) they provide an unlimited supply of pluripotent stem
cells without the need for embryonic tissues, (3) they are
amenable to gene correction approaches, and (4) they are now
routinely derived.
DIRECTED DIFFERENTIATION OF iPSCS
INTO LUNG EPITHELIUM
Over the past decade, many groups contributed to major progress
toward generating lung epithelial cells from iPSCs (Table 1).
Directed differentiation refers to the approach of recapitulating,
in vitro, the key embryonic developmental milestones that lead
to the specification of the cell(s) of interest. This is typically
achieved through the stepwise addition of signaling factors
identified in mouse studies of organogenesis. The field of lung
directed differentiation has evolved from generating relatively
immature lung epithelial cells to recent reports of increasingly
sophisticated protocols that produce relatively mature and
functional lung epithelial cells that are currently being applied to
lung disease modeling, drug screening and the first forays into
in vivo transplantation.
In order to understand the directed differentiation process,
a brief overview of lung development is first required. The lung
develops from the foregut endoderm and is first identified by
the expression of Nkx2-1, a key transcription factor. Nkx2-1
is first detected at E9.0 in mice and day 28 in human embryos
(Lazzaro et al., 1991; Morrisey and Hogan, 2010). During
the first stages of lung organogenesis Nkx2-1+ cells form
two primary lung buds and the adjacent foregut separates
into two tubes, a ventral trachea and dorsal esophagus.
During the pseudoglandular stage, the lung buds undergo
branching morphogenesis and proximal-distal patterning.
This process, controlled by reciprocal signaling between
the lung epithelium and surrounding mesenchyme, gives
rise to a highly branched airway tree composed of basal,
secretory, multi-ciliated and neuroendocrine cells and an
alveolar compartment composed of types 1 and 2 pneumocytes.
A number of signaling pathways are involved in the epithelial-
mesenchymal interactions that control these stages of lung
development including SHH, WNTs, FGFs, retinoic acid and
BMPs (Hawkins et al., 2016).
To differentiate iPSCs into lung epithelial cells researchers
seek to reproduce these key developmental events in vitro.
The first major developmental stage in the road map of
lung development is the formation of definitive endoderm.
Mimicking the in vivo patterning of the primitive streak, the
addition of the Nodal agonist Activin-A to iPSCs or ESCs
produces a highly enriched population of endodermal cells
that express classic endoderm markers (including FOXA2 and
SOX17) (Kubo et al., 2004; D’Amour et al., 2005; Christodoulou
et al., 2011). The protocols to generate definitive endoderm
are now well established and form the basis of all endodermal
differentiation protocols including lung, liver, pancreas and
intestine. The next important developmental step is directing
definitive endodermal cells (FOXA2+) toward an anterior-
foregut fate (FOXA2+/SOX2+), analogous to the anterior-
posterior axis patterning in the primitive gut tube. The field of
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lung directed differentiation is relatively new and not surprisingly
the published protocols from different groups vary significantly
in terms of the timing and combination of growth factors and
inhibitors applied at different stages. For example, differing
approaches have achieved in vitro foregut patterning. In one
method antagonism of BMP and TGFβ pathways after endoderm
induction was identified as the most potent condition to maintain
FOXA2 expression, and to induce the anterior endoderm marker
SOX2 while suppressing a hindgut fate that expresses CDX2
(Green et al., 2011). The inclusion of BMP and/or TGFβ
inhibition has been adopted by others (Longmire et al., 2012;
Mou et al., 2012; Firth et al., 2014; Dye et al., 2015; Hawkins
et al., 2017). Alternative approaches include the combination of
FGF2 and SHH signaling (Wong et al., 2012). Lung specification
is the next major developmental milestone and is indicated by
the expression of NKX2-1 in foregut endoderm cells. Several
groups have concluded that WNT, through recombinant WNT3a
or glycogen synthase kinase 3 inhibitors, BMP4, and retinoic
acid pathway activation are required for lung specification
(Huang et al., 2013; Gotoh et al., 2014; Hawkins et al.,
2017). Others have developed quite different approaches that
led to specification of a lung program, for example using a
combination of BMP and TGFβ inhibition, plus SHH and WNT
activation (Dye et al., 2015). Early reports demonstrated lung
competence of these cells via upregulation of differentiation
markers over time. However, both proximal and distal lung
markers were frequently present suggesting that the precise
signals patterning lung progenitors toward proximal vs. distal
fates and to specific differentiated cell types are incompletely
known. Competence of these cells to differentiate into functional
airway lineages was demonstrated by transitioning to air-liquid
interface conditions used to differentiate primary HBECs, or
by injecting the cells into the flank or kidney capsule of
immune-deficient mice (Wong et al., 2012; Huang et al., 2013;
Firth et al., 2014). More recently, there has been progress in
generating lung organoids from iPSC-derived lung epithelium,
reminiscent of the 3-D organization of lung tissue (Gotoh
et al., 2014; Dye et al., 2015; Chen et al., 2017; Hawkins
et al., 2017; Miller et al., 2018). In some cases, these protocols
involve the co-development of mesodermal and endodermal
compartments. To overcome the heterogeneity of cell types
produced in these protocols, fluorescent lineage reporters or
surface markers have been employed to prospectively isolate
the lung epithelial cells of interest. Surface markers including
Carboxypeptidase M or the combination of CD47hi/CD26lo
were identified to isolate immature NKX2-1+ lung epithelial
cells and to generate lung epithelial organoids depleted of
other endodermal and mesodermal cell types (Gotoh et al.,
2014; Hawkins et al., 2017). Although less relevant as a cell-
based therapy for CF, it is worth highlighting some of the
most compelling progress toward generating relatively mature,
functional type 2 pneumocytes from iPSCs. Two groups,
adopting the approach of targeting fluorescent reporters to
the endogenous SFTPC locus, developed similar protocols to
isolate and propagate long term a population of SFTPC+ cells
highly reminiscent of alveolar type 2 cells (Jacob et al., 2017;
Yamamoto et al., 2017).
DIRECTED DIFFERENTIATION OF iPSCS
INTO AIRWAY EPITHELIUM
To cure CF airway disease, a cell-based therapy would ideally
replace the CFTR-expressing columnar luminal epithelial
cells, including terminally differentiated multi-ciliated cells
and perhaps ionocytes, but also the stem/progenitor cells
that maintain the luminal cells. A number of groups have
demonstrated the feasibility of generating CFTR expressing
airway epithelium composed of multi-ciliated cells and cells
reminiscent of basal and secretory cells (Wong et al., 2012;
Firth et al., 2014; Konishi et al., 2016; McCauley et al., 2017).
These airway epithelial cells broadly recapitulate the CFTR
dysfunction seen in the primary cells of CF patients when
interrogated using established CFTR functional assays including
ion transport in Ussing chambers and forskolin-induced
spheroid swelling. In an important proof-of-concept study,
Crane et al., demonstrated the correction of the F508del
mutation in iPSCs using zinc-finger nucleases and restoration
of CFTR function in those cells after lung differentiation
(Crane et al., 2015). Based on our current knowledge, an
ideal iPSC-derived candidate cell for engraftment into CF
airways is the airway basal cell. A number of groups have
described the presence of a subset of basal-like cells after
directed lung differentiation as evidenced by the expression
of key basal cell markers (e.g., TP63, KRT5) (Dye et al., 2015;
Konishi et al., 2016; Chen et al., 2017; Hawkins et al., 2017;
McCauley et al., 2017). However, the efficient derivation
of bonafide basal cells, as evidenced by transcriptional
profiling and functional demonstration of differentiation
into multi-ciliated and secretory cells comparable to those
generated by primary basal cell controls, has not yet been
convincingly achieved.
IN VIVO ENGRAFTMENT OF
iPSC-DERIVED LUNG
EPITHELIAL CELLS
Provided that it is possible to derive a candidate cell type
in vitro, would that cell engraft and function once transplanted?
This is a major question now facing this field and very little
is known about the in vivo potential of iPSC-derived cells
in the lung. Recently, the first report of human iPSC-derived
lung epithelial cells engrafting in a murine lung injury model
was described (Miller et al., 2018). Miller et al., identified
conditions to capture and expand cells with a transcriptional
profile similar to the multipotent cells of the developing lung
bud tip. The iPSC-derived lung tip cells were delivered intra-
tracheally into immunocompromised mice following airway
injury with naphthalene. Engrafted cells persisted for up to
6 weeks after transplantation and these cells had adopted
a predominantly airway and mostly secretory cell fate with
rare multi-ciliated cells. This study is an important first step
establishing the feasibility of using animal models to develop
engraftment strategies, and suggests that the micro-environment
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or niche may play an important role in the cell fate decisions of
transplanted cells.
CHALLENGES FACING iPSCS AS A
CELL-BASED THERAPY
Despite the progress made in the field of iPSC directed
differentiation into lung cells, there are major challenges facing
the application of cell-based therapy for the treatment of CF.
To date, the derivation of a pure population of airway epithelial
cells from iPSCs in sufficient numbers to engraft in human
airways has not yet been achieved. How will adequate numbers
of differentiated cells be generated for patients? How safe
are iPSC-derived lung epithelial cells? The same factors and
culture conditions that allow for the unimpeded self-renewal and
pluripotency also predispose to tumorigenicity; in fact, a survey
of the exomes of 117 human iPSC lines identified nine with
mutations in the tumor suppressor gene, TP53, with evidence
that iPSCs with the mutation had a survival advantage (Ben-
David and Benvenisty, 2011; Merkle et al., 2017). Other groups
have confirmed that gene editing with CRISPR/Cas9 selects
against cells with a normal p53 pathway (Haapaniemi et al.,
2018; Ihry et al., 2018). Initially iPSCs were generated using viral
vectors that randomly integrated into the genome (Takahashi
and Yamanaka, 2006). This approach raised obvious concerns
about the malignant potential of iPSCs if an important tumor
suppressor locus was disrupted. A non-integrating episomal-
based method, such as Sendai virus, is a more logical approach
to derive clinical-grade iPSCs (Fusaki et al., 2009). The delivery
of safe cells will require a robust and reproducible process to
generate iPSCs and differentiated cells, compliant with relevant
current good manufacturing practice (cGMP) and regulatory
agency approval. Confirmation that the resulting cells are free of
integrations and somatic mutations will be needed (Baghbaderani
et al., 2015). Transplanted cells will require in vitro gene-
correction to express functional CFTR. With reprogramming
and passaging, and additional time needed to gene-edit and
expand cells, the probability of somatic mutations will increase.
Furthermore, the process of gene-editing brings additional risk of
off-target double-stranded breaks with the potential of disrupting
other genetic loci (Zhang et al., 2015). As the goal of cell-based
therapy is to replace diseased endogenous lung epithelium with
engineered cells, it will be essential to generate pure populations
of lung epithelial cells that are highly similar to their in vivo
counterparts. The field is relatively new and most reports have
not focused on the non-lung cells that might also be produced
during the differentiation process. For example, an iPSC line
expressing GFP from the NKX2-1 locus (NKX2-1GFP) identified
significant variability in the percentage of GFP+ cells, and
analysis of the GFP− population confirmed expression of liver
and intestine markers (Hawkins et al., 2017; Serra et al., 2017).
Even after a purification step to sortNKX2-1GFP+ cells, McCauley
et al. applied single-cell RNA sequencing to airway and alveolar
iPSC-derived organoids and identified distinct populations of
non-lung endoderm including hepatic-like and gastric-like cells
(McCauley et al., 2018). The quest to generate pure populations
of well-defined lung epithelial cells will continue and be aided by
powerful new techniques such as single-cell RNA sequencing and
expanding knowledge of the transcriptional profile and signaling
pathways involved in human lung development (Treutlein et al.,
2014; Nikolić et al., 2017; Miller et al., 2018). The appropriate
number of donor cells required to repopulate a sufficient portion
of the diseased airway epithelium is unknown. CFTR levels
15–20% of normal airway expression may be enough to effectively
treat CF airway disease (McKone et al., 2003). Building on these
aforementioned advances, the ultimate final hurdle to a cell-based
therapeutic approach for CF is engraftment.
ENGRAFTMENT
The gold standard for cell-based therapy is hematopoietic
cell transplantation. This now commonplace and life-saving
procedure relies on delivering hematopoietic progenitor cells
after inducing tissue receptivity through marrow-ablative doses
of cytotoxic agents and radiation. The term engraftment is used
to describe the reconstitution of host bone marrow by donor
cells. For CF, successful airway engraftment is thought of in
similar terms, recipient airway priming, donor cell survival and
regeneration of the airway epithelium (Figure 2). The ideal
strategy to deliver a cell-based therapy for CF, or any lung disease,
has yet to be developed and the prospect of deliberately injuring
the lungs of CF recipients to ablate endogenous cells is daunting.
An ideal engraftment strategy would involve the minimal airway
injury necessary, in particular to the small airways, to promote
a microenvironment conducive to long-lived engraftment of
cells in numbers sufficient to restore CFTR function. There
are many hurdles the scientific community must overcome to
achieve human airway engraftment such as determining: (1) the
most suitable cell type(s), (2) the methods to safely scale-up cell
production, (3) the optimal injury, (4) supportive measures for
oxygenation/ventilation and (5) methods to control mucus and
infection to allow engraftment of cells. Despite these challenges,
there are promising reports of effective cell therapies for other
organ systems that support the overall feasibility of this approach.
Based on pioneering work from the laboratory of Howard
Green, autologous epidermal keratinocytes have been extensively
evaluated as treatment for burns (Green et al., 1979; Ter Horst
et al., 2018). Recently, transgenic autologous keratinocytes with
a correct copy of a gene mutated in the blistering skin disease
junctional epidermolysis bullosa were used to replace nearly
the entire epidermis of a critically ill child with 60% skin
loss, miraculously allowing hospital discharge and return to
school (Hirsch et al., 2017). This remarkable achievement not
only alleviated patient suffering, but also provided vital insights
about epidermal keratinocyte stem cell dynamics, indicating the
importance of long-lived stem cells for epidermal restoration.
Additional experience comes from corneal limbal epithelial stem
cell transplantation in which damage to one eye can be treated
with autologous stem cells from the contralateral eye (Rama
et al., 2017; Sasamoto et al., 2018). In the lung field, a number
of groups have recently reported evidence of lung engraftment
in animal models (Rosen et al., 2015; Vaughan et al., 2015;
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FIGURE 2 | A Cell-Based Therapy Model for CF. (A) The pre-treatment CF large airway. (B–D) A depiction of cell-based therapy in three steps: (B) Mucus removal
and transient preconditioning of the airway epithelium, potentially requiring luminal epithelial surface cell loss and partial epithelial denudation; (C) Delivery of
CFTR-corrected stem and progenitor cells to the surface epithelium and possibly the submucosal glands; (D) Differentiation of delivered CFTR-corrected cells into all
relevant cell types, restoration of functional CFTR ion-transport and a return to normal airway physiology.
Ghosh et al., 2017; Nichane et al., 2017; Ma et al., 2018; Miller
et al., 2018). Here we will briefly review this progress and
highlight important next steps.
A number of injury models, including naphthalene, sulfur
dioxide, radiation and detergents, have been developed to
study the biology of the airway epithelium (Lamb and Reid,
1968; Plopper et al., 1992; Borthwick et al., 2001; Leblond
et al., 2009; Rosen et al., 2015). It is unclear to what extent,
if any, these models might be used in humans but they
have provided a platform to study and develop engraftment
strategies. Embryonic lung, both mouse and human, contain
stem/progenitor populations with engraftment capacity (Rosen
et al., 2015; Nichane et al., 2017). In one approach, intravenous
administration of a single cell suspension of whole canalicular
stage lung (mouse E15-16 or human week 20–22) into mice pre-
conditioned with both naphthalene and total body irradiation,
resulted in epithelial, mesenchymal, and endothelial patches of
engrafted cells (Rosen et al., 2015). Higher rates of chimerism
were detected in mouse-into-mouse compared to human-into-
mouse experiments. It is surprising that intravenous delivery of
a mixture of embryonic lung cell types resulted in homing of
cells to their unique anatomic compartments. Further work is
required to understand the safety of this approach including the
consequence of cells being delivered to the wrong compartment
within the lung or even to other organs. In terms of an approach
for CF, the majority of epithelial engrafted cells had an alveolar
phenotype although some airway-like cells were detected and
some expressed CFTR. Interestingly, the co-administration of
mesenchymal and endothelial cells was associated with improved
epithelial cell engraftment. The multitude of practical, ethical
and political issues surrounding the use of fetal tissue make
this an unlikely future option for cell-based therapy. However,
iPSCs may provide access to autologous cells at embryonic
time points with capacity to engraft (Miller et al., 2018). Adult
airway epithelial cells can also engraft in the lung (Vaughan
et al., 2015; Ghosh et al., 2017; Nichane et al., 2017). The
environment induced by H1N1 influenza infection has garnered
much interest for its engraftment potential (Kumar et al., 2011;
Vaughan et al., 2015). The viral infection causes widespread
damage to the airway and alveolar epithelium and activates
rare immature (TP63+/KRT5−) basal cells in the small airways
(Yang et al., 2018). Orthotopic transplantation of a variety
of airway epithelial cells into influenza-injured mice led to
varying levels of engraftment (Vaughan et al., 2015). Perhaps
most relevant to the CF field is a recent report of successful
engraftment of primary airway basal cells into naphthalene
injured mice (Ghosh et al., 2017). Transplanted mouse or human
basal cells reconstituted patches of epithelium in the trachea
and small airways with evidence of multi-lineage differentiation
into secretory and multi-ciliated cells. Themes common to each
of the above experiments include: (1) lung injury is required
for engraftment of donor cells, (2) different injury models
likely result in unique regenerative niches and (3) successful
strategies to date suggest multipotent input donor cells are the
most promising candidates for engraftment. Looking forward,
a number of approaches might accelerate the field of cell-based
therapy for lung disease. Engraftment after hematopoietic cell
transplantation is monitored by sampling the peripheral blood.
Assessing lung engraftment is far more challenging. Methods
to interrogate whether donor cells are functionally integrated
into the airway epithelium will be essential. Animal studies to
optimize injury models and the efficiency, function and safety
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of engrafted cells are necessary, but are rate-limiting
due to low throughput, particularly in larger animals.
Developing non-lethal experimental methods, including
targeted airway injury and bioluminescent reporter cell
lines to track engrafted cells in real-time without the
need for necropsy would increase the efficiency of animal
engraftment studies.
Methods to incite a targeted, clinically tolerable airway
epithelial injury have been tested in humans albeit not in
the context of cell-based therapy. Bronchial thermoplasty,
an FDA-approved treatment for refractory severe persistent
asthma, delivers brief thermal energy to the airways via flexible
bronchoscopy and leads to initial epithelial sloughing and a
prolonged decrease in smooth muscle with improvement in
asthma severity (Miller et al., 2005). In a small pilot study,
airway delivery of a metered liquid nitrogen cryospray via
bronchoscopy resulted in airway epithelial damage followed
by regeneration (Slebos et al., 2017). An alternative approach,
with potential for clinical translation, is targeted airway de-
epithelialization achieved by instilling mild detergents intra-
tracheally (Dorrello et al., 2017). Despite the many limitations
of these approaches in the context of CF, including the
small size and large number of airways needed to treat
CF, they provide preliminary support for the feasibility of a
human injury platform. The situation is further complicated
for targeting CF in more advanced disease where successful
cell-based therapy must also overcome a highly inflamed,
architecturally distorted organ characterized by thick mucus
and superinfection. Similar to the blood product and growth
factor support necessary after hematopoietic cell transplant,
lung engraftment strategies will likely require lung supportive
measures. The advances and more widespread use of extra-
corporeal membrane oxygenation (ECMO) provides a means
of supporting oxygenation during respiratory failure (Squiers
et al., 2016). Advances in the technology to maintain human
lungs using ex vivo lung perfusion (EVLP) may provide
insights into supporting the injured and regenerating lung
(Makdisi et al., 2017). Future approaches for cell-based therapy
incorporating these evolving technologies may be necessary.
Alternatively, devising injury-independent strategies to promote
lung engraftment of therapeutic cells may be an avenue for future
research and development.
CONCLUSION
To date, CF remains the most common life-limiting hereditary
lung disease. Decades of work resulted in important strides
to understand molecular mechanisms in CF and treatment
options for many patients. Despite this progress, a subset of
patients lack effective treatment options and cell-based therapies
could theoretically cure CF lung disease. The ideal cell type
for this purpose would repopulate the airway epithelium with
autologous, functional, and CFTR-expressing cells. Progress in
our understanding of airway epithelial biology and endogenous
stem/progenitor populations has revealed a number of candidate
cell types for airway regeneration, in particular basal cells.
The recent revolution in gene-editing techniques means genetic
correction of the CFTR mutation in basal cells will likely be
achieved in the near future and would provide a source of
autologous airway stem cells with the normal CFTR sequence.
In the iPSC field, directed differentiation protocols have evolved
from initial studies demonstrating the presence of immature
lung-like cells to more recent reports of increasingly efficient
protocols to derive functional alveolar and airway epithelial cells.
We have detailed some of the major challenges that must be
overcome both in terms of generating the cells of interest and
engrafting those cells in a safe and effective manner. While there
is work yet to be done, there is cautious optimism that a curative
cell-based therapy for CF will be achieved in the future.
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